Загрузка...

U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma

On March 29, 2011, the U.S. Food and Drug Administration approved peginterferon alfa-2b (PEG-IFN) (Sylatron™; Schering Corporation, Kenilworth, NJ) for the adjuvant treatment of melanoma patients with microscopic or gross nodal involvement following definitive surgical resection including complete l...

Полное описание

Сохранить в:

Библиографические подробности
Главные авторы:	Herndon, Thomas M., Demko, Suzanne G., Jiang, Xiaoping, He, Kun, Gootenberg, Joseph E., Cohen, Martin H., Keegan, Patricia, Pazdur, Richard
Формат:	Artigo
Язык:	Inglês
Опубликовано:	AlphaMed Press 2012
Предметы:	Regulatory Issues: FDA
Online-ссылка:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3481898/ https://ncbi.nlm.nih.gov/pubmed/23002124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0123
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma

Схожие документы